HIGH-DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE AND BCNU WITH NON-CRYOPRESERVED AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR POOR PROGNOSIS MALIGNANT-LYMPHOMA

被引：5

作者：

KOPPLER, H

PFLUGER, KH

KLAUSMANN, M

HAVEMANN, K

机构：

[1] Zentrum für Innere Medizin, Abteilung Hämatologie, Philipps-Universität, Marburg

来源：

LEUKEMIA & LYMPHOMA | 1992年 / 6卷 / 03期

关键词：

AUTOLOGOUS BONE MARROW TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; HODGKINS DISEASE; NON-HODGKINS LYMPHOMA;

D O I：

10.3109/10428199209064898

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

20 patients with poor prognosis malignant lymphoma (Hodgkin's disease 8, high grade non-Hodgkin's lymphoma 12) were treated with high-dose cyclophosphamide (120 mg/kg), etoposide (2100 mg/m2) and BCNU (400mg/m2) followed by reinfusion of autologous non-frozen bone marrow, which had been stored for 72 hours at 4°C. All evaluable patients (19/20) had a full haematopoietic reconstitution. Median time to achieve neutrophils > 500 μl was 26 days (range 15-39) and median time to achieve an unsupported platelet count >20000/μl was 29 days (range 12-55). During a median follow-up of 10.5 months (range 2-36) 2 of 8 patients with Hodgkin's disease and 3/12 patients with non-Hodgkin's lymphoma relapsed after a median of 4.5 months (range 1-6). The projected event-free survival at 24 months was 61% and 70% for patients with non-Hodgkin's lymphoma and Hodgkin's disease respectively. We conclude that high-dose chemotherapy with non-frozen autologous bone marrow transplantation is safe in terms of haematopoietic reconstitution and the preliminary follow-up data suggest a useful efficacy. The procedure is easy to perform without requiring costly cryopreservation. © 1992 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：219 / 222

页数：4

共 24 条

[1]

Armitage J.O., Vose J.M., Bierman P.J., Salvage therapy for patients with non-Hodgkin's lymphoma, Monogr. J. Natl. Cancer Inst, 10, pp. 39-43, (1990)

[2]

Gribben J.G., Goldstone A.H., Linch D.C., Taghipour G., McMillan A.K., Souhami R.L., Earl H., Richards J.D., Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy, J. Clin. Oncol, 7, pp. 1621-1629, (1989)

[3]

Vose J.M., Armitage J.O., Bierman P.J., Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation, Am. J. Med, 87, pp. 285-288, (1989)

[4]

Freedman A.S., Takvorian T., Anderson K.C., Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse, J. Clin. Oncol, 8, pp. 784-791, (1990)

[5]

Colombat P., Gorin N.C., Lemonnier M.P., The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin's lymphomas, J. Clin. Oncol, 8, pp. 630-637, (1990)

[6]

Petersen F.B., Appelbaum F.R., Hill R., Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle, J. Clin. Oncol, 8, pp. 638-647, (1990)

[7]

Bonadonna G., Santoro A., Current issues in the management of advanced Hodgkin's disease, Blood Rev, 4, (1990)

[8]

Gribben J.G., Linch D.C., Singer C.R.J., McMillan A.K., Jarret M., Goldstone A.H., Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation, Blood, 73, pp. 340-344, (1989)

[9]

Jones R.J., Piantadosi S., Mann R.E., High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease, J. Clin. Oncol, 8, (1990)

[10]

Spinolo J.A., Jagannath S., Dicke K.A., High-dose combination chemotherapy with cyclophosphamide, carmustine, etoposide, and autologous bone marrow transplantation in 60 patients with relapsed Hodgkin's disease: the M.D. Anderson experience, Recent Results Cancer Res, 117, pp. 233-238, (1989)

← 1 2 3 →